Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This pharmacological regimen refers to the combined use of magnesium sulfate (MgSO4) and rocuronium bromide, specifically utilizing a 'priming' technique, to facilitate rapid neuromuscular blockade during the induction of general anesthesia. Magnesium sulfate acts as a calcium antagonist at the presynaptic nerve terminal, inhibiting the release of acetylcholine, and also reduces the sensitivity of the post-junctional membrane, thereby potentiating the effects of neuromuscular blockers. Rocuronium is a non-depolarizing neuromuscular blocking agent (NMBA) that competitively antagonizes nicotinic acetylcholine receptors at the neuromuscular junction. The priming principle involves administering a small, sub-paralyzing dose of rocuronium (the priming dose) several minutes before the main intubating dose to occupy a portion of the receptors, which significantly accelerates the onset of action. This specific protocol was investigated by Seoul National University Bundang Hospital to determine if the addition of MgSO4 to a rocuronium priming regimen further enhances the speed and quality of muscle relaxation for tracheal intubation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on magnesium sulfate + rocuronium.